Stockreport

Clearmind Medicine Enters into Development Agreement to Advance Intranasal Formulation for its Proprietary Non-Hallucinogenic Neuroplastogen MEAI

Clearmind Medicine Inc. - Common Shares  (CMND) 
PDF Collaboration aims to enhance bioavailability and support clinical advancement of Clearmind’s lead MEAI candidate for addiction-related and other CNS disorders Vancouve [Read more]